A comprehensive health-related corporate group with a human face
First written in FY2018. 9 of 11 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「Through its 3 business activities—pharmaceutical-related businesses, biomaterials and healthcare—the Company creates distinctive products that meet needs, ensures a stable supply of products of appropriate quality, and maximizes product value.」
The Company continues to pursue a vision of achieving distinctive products, a stable supply and maximum product value through its 3 businesses. - FY2026-H1RestatedAnnual report
「Our group (the Company and its consolidated subsidiaries, hereinafter the same) has adopted the long-term vision of “growing as a distinctive life and health-related corporate group whose value is recognized globally by addressing medical and healthcare needs.”」
The vision of growing into a distinctive life sciences and healthcare group is being reconfirmed as a premise of the 25-27 Medium-Term Management Plan. - FY2025RestatedAnnual report
「Through its 3 business activities—pharmaceutical-related businesses, biomaterials and healthcare—the Company creates distinctive products that meet needs, ensures a stable supply of products of appropriate quality, and maximizes product value.」
The direction of growing into a distinctive life sciences and healthcare group through pharmaceuticals, biomaterials and healthcare is being reconfirmed. - FY2023RestatedAnnual report
「Mochida Pharmaceutical Group aims to grow into a distinctive life sciences and healthcare group whose value is recognized globally by meeting medical and healthcare needs, based on its corporate philosophy of “developing distinctive, forward-looking products continuously, actively participating in the world of medicine, and thereby contributing to human health and welfare.”」
The long-term vision of growing into a distinctive life sciences and healthcare group is being reconfirmed in the Basic Sustainability Policy. - FY2022RestatedAnnual report
「We will grow as a distinctive life and health-related corporate group whose value is recognized globally by addressing medical and healthcare needs.」
The Company is reconfirming its vision of growing from a diversified healthcare group into a distinctive life sciences and healthcare group as its long-term vision. - FY2021ReframedAnnual report
「The Company aims to become a distinctive life sciences and healthcare group whose value is recognized globally.」
The description of the target corporate vision has changed from “a distinctive, diversified healthcare group with a recognizable identity” to “a distinctive life sciences and healthcare group.” - FY2020RestatedAnnual report
「Since its founding in 1913, the Company has pursued a diversified healthcare business centered on the research and development of original pharmaceuticals under the philosophy of “foresight, originality and research.”」
The long-term business vision of becoming a diversified healthcare company centered on pharmaceutical R&D is being reconfirmed. - FY2020-Q3RestatedAnnual report
「Since its founding in 1913, the Company has pursued a diversified healthcare business centered on the research and development of original pharmaceuticals under the philosophy of “foresight, originality and research.”」
The long-term business vision of becoming a diversified healthcare company centered on pharmaceutical R&D is being reconfirmed. - FY2020-Q1RestatedAnnual report
「Since its founding in 1913, the Company has pursued a diversified healthcare business centered on the research and development of original pharmaceuticals under the philosophy of “foresight, originality and research.”」
The long-term business vision of becoming a diversified healthcare company centered on pharmaceutical R&D is being reconfirmed. - FY2019RestatedAnnual report
「In line with its corporate philosophy of developing distinctive, forward-looking products continuously, actively participating in the world of medicine, and thereby contributing to human health and welfare, the Group aims to become a distinctive, diversified healthcare group with a recognizable identity, centered on its pharmaceutical business and encompassing its healthcare business and new fields related to these business areas.」
The policy of becoming a distinctive, diversified healthcare group with a recognizable identity, encompassing pharmaceuticals, healthcare and related new fields, is being reconfirmed. - FY2018First statedAnnual report
「The Company aims to become a distinctive, diversified healthcare group with a recognizable identity, centered on its pharmaceutical business and encompassing its healthcare business and new fields related to these business areas.」
The Company has stated its vision as a corporate group encompassing pharmaceuticals, healthcare and related fields.